Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm May 27, 2026 08:01PM
Gyre Therapeutics receives NMPA acceptance for liver fibrosis drug application May 12, 2026 04:06PM
Gyre Therapeutics (GYRE) Misses Q1 EPS by 3c May 7, 2026 06:29AM
Gyre Therapeutics receives priority review in China for liver fibrosis drug Mar 17, 2026 07:00AM
Gyre Therapeutics (GYRE) Misses Q4 EPS by 7c Mar 12, 2026 07:05AM


Mar 2, 2026 11:58AM H.C. Wainwright Reiterates Buy Rating on Gyre Therapeutics (GYRE) following acquisition announcement
Jan 5, 2026 07:13AM Gyre Therapeutics receives CDE alignment on conditional approval pathway for Hydronidone
Nov 7, 2025 04:13PM Gyre Therapeutics (GYRE) Misses Q3 EPS by 2c
Oct 16, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Gyre Therapeutics (GYRE)
Oct 10, 2025 05:04AM Jefferies Starts Gyre Therapeutics (GYRE) at Buy
Aug 26, 2025 07:10AM H.C. Wainwright Starts Gyre Therapeutics (GYRE) at Buy
Aug 11, 2025 04:46PM Gyre Therapeutics (GYRE) Misses Q2 EPS by 2c
Jun 10, 2025 07:07AM Gyre Therapeutics (GYRE) Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
May 23, 2025 05:53AM Gyre Therapeutics (GYRE) Offering 2.2M Shares at $9 Per
May 22, 2025 04:03PM Gyre Therapeutics (GYRE) announces Hydronidone met endpoint in Phase 3 trial
May 22, 2025 04:03PM Gyre Therapeutics (GYRE) Announces Proposed Underwritten Public Offering of Common Stock
May 9, 2025 04:48PM Gyre Therapeutics (GYRE) Misses Q1 EPS by 3c
Mar 31, 2025 07:02AM Gyre Therapeutics (GYRE) Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Mar 27, 2025 07:00AM Gyre Therapeutics (GYRE) Announces Publication of Protocol for Phase 3 Trial Evaluating F351
Mar 17, 2025 05:26PM Gyre Therapeutics (GYRE) Reports In-Line Q4 EPS
Jan 6, 2025 07:01AM Gyre Therapeutics (GYRE) Appoints Ping Zhang to its Board
Nov 14, 2024 04:49PM Gyre Therapeutics (GYRE) Files Mixed Shelf
Nov 13, 2024 05:07PM Gyre Therapeutics, Inc. (GYRE) Reports Q3 EPS of $0.01
Aug 13, 2024 07:22AM Gyre Therapeutics, Inc. (GYRE) Reports Q2 EPS of $0.01
Aug 8, 2024 04:09PM Gyre Therapeutics (GYRE) Appoints David M. Epstein to its Board
Jul 2, 2024 04:06PM Gyre Therapeutics (GYRE) Announces China’s NMPA Approval of Avatrombopag Maleate Tablets